All In Biotech

Drug Trial Radar · NCT02296138

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]

Last checked: Nov 19, 2026Latest source record: Jun 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,903 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,903

Actual

Start

Jan 13, 2015

Primary completion

Mar 8, 2017

Study completion Mar 29, 2017

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • olodaterolDrug

    fixed dose combination

  • tiotropiumDrug

    fixed dose combination

  • tiotropiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.Time frame: From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days

Locations

818 sites in 51 countries. Site status is shown where the registry gives one.

  • 1237.19.10039 Boehringer Ingelheim Investigational Site

    Andalusia, Alabama

  • 1237.19.10009 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1237.19.10077 Boehringer Ingelheim Investigational Site

    Florence, Alabama

  • 1237.19.10115 Boehringer Ingelheim Investigational Site

    Jasper, Alabama

  • 1237.19.10069 Boehringer Ingelheim Investigational Site

    Flagstaff, Arizona

  • 1237.19.10085 Boehringer Ingelheim Investigational Site

    Peoria, Arizona

  • 1237.19.10110 Boehringer Ingelheim Investigational Site

    Lincoln, California

  • 1237.19.10118 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1237.19.10074 Boehringer Ingelheim Investigational Site

    Poway, California

  • 1237.19.10157 Boehringer Ingelheim Investigational Site

    Lafayette, Colorado

  • 1237.19.10142 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1237.19.10133 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 1237.19.10093 Boehringer Ingelheim Investigational Site

    Stamford, Connecticut

  • 1237.19.10029 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1237.19.10106 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1237.19.10020 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1237.19.10000 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1237.19.10135 Boehringer Ingelheim Investigational Site

    St. Petersburg, Florida

  • 1237.19.10145 Boehringer Ingelheim Investigational Site

    Tamarac, Florida

  • 1237.19.10066 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1237.19.10032 Boehringer Ingelheim Investigational Site

    Winter Park, Florida

  • 1237.19.10080 Boehringer Ingelheim Investigational Site

    Duluth, Georgia

  • 1237.19.10011 Boehringer Ingelheim Investigational Site

    Gainesville, Georgia

  • 1237.19.10112 Boehringer Ingelheim Investigational Site

    Lawrenceville, Georgia

  • 1237.19.10037 Boehringer Ingelheim Investigational Site

    Eagle, Idaho

  • 1237.19.10130 Boehringer Ingelheim Investigational Site

    O'Fallon, Illinois

  • 1237.19.10065 Boehringer Ingelheim Investigational Site

    River Forest, Illinois

  • 1237.19.10122 Boehringer Ingelheim Investigational Site

    Muncie, Indiana

  • 1237.19.10063 Boehringer Ingelheim Investigational Site

    Topeka, Kansas

  • 1237.19.10048 Boehringer Ingelheim Investigational Site

    Bowling Green, Kentucky

  • 1237.19.10108 Boehringer Ingelheim Investigational Site

    Fort Mitchell, Kentucky

  • 1237.19.10109 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 1237.19.10095 Boehringer Ingelheim Investigational Site

    Opelousas, Louisiana

  • 1237.19.10113 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

  • 1237.19.10139 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

  • 1237.19.10117 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 1237.19.10083 Boehringer Ingelheim Investigational Site

    Columbia, Maryland

  • 1237.19.10072 Boehringer Ingelheim Investigational Site

    Hollywood, Maryland

  • 1237.19.10027 Boehringer Ingelheim Investigational Site

    Fall River, Massachusetts

  • 1237.19.10138 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

Showing 40 of 818 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.